Avecho Biotechnology Limited (ASX:AVE)

Australia flag Australia · Delayed Price · Currency is AUD
0.0120
+0.0010 (9.09%)
Apr 29, 2026, 4:13 PM AEST
140.00%
Market Cap 40.41M
Revenue (ttm) 1.24M
Net Income (ttm) -4.42M
Shares Out 3.67B
EPS (ttm) -0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,456,853
Average Volume 5,277,790
Open 0.0110
Previous Close 0.0110
Day's Range 0.0110 - 0.0120
52-Week Range 0.0030 - 0.0120
Beta 0.94
RSI 62.54
Earnings Date May 28, 2026

About Avecho Biotechnology

Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company dev... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 15
Stock Exchange Australian Securities Exchange
Ticker Symbol AVE
Full Company Profile

Financial Performance

In 2025, Avecho Biotechnology's revenue was 1.24 million, an increase of 9.28% compared to the previous year's 1.13 million. Losses were -4.42 million, 41.5% more than in 2024.

Financial Statements

News

Avecho Biotechnology Transcript: NWR Virtual Healthcare Conference

A proprietary CBD capsule for insomnia, enhanced with TPM technology, is in a pivotal phase III trial with interim results due in June. A major licensing deal with Sandoz secures Australian rights, with significant revenue potential and global expansion opportunities.

5 weeks ago - Transcripts